The chronic activity of PARPs can induce NAD+ depletion, which can result in the shutdown of mitochondrial function and glycolytic slowdown through the reduction of NAD+ availability for other processes such as the activation of SIRTs and elevated PARP activation through ROS increase can lead to several diseases affecting major organs (Cantó et al., 2013; Bai, 2015), including increased tumor growth; therefore PARP inhibitors are actively researched (Li et al., 2022). This evidence concerns the gene PARP1 and neoplasm.